Sosa-Estani Sergio, Segura Elsa Leonor
Centro Nacional de Diagnóstico e Investigación de Endemo-epidemias (CeNDIE), Ministerio de Salud y Ambiente, Buenos Aires, Argentina.
Curr Opin Infect Dis. 2006 Dec;19(6):583-7. doi: 10.1097/01.qco.0000247592.21295.a5.
The aim of this review is to describe knowledge, mainly of the last 15 years, that changed criteria for specific treatment against Trypanosoma cruzi infection.
Over the past 15 years, there has been an increase in the use of new methodologies to evaluate the efficacy of antiparasitic treatments. These tools showed that the evaluation period for trypanocidal treatment effectiveness could be shortened. Based on the hypothesis that Chagas' cardiomyopathy may indeed be triggered by persistent parasitic infection, it seems plausible that trypanocidal therapy may delay, reduce or prevent the progression to the disease.
Based on the present knowledge, we can assume that every patient infected with Trypanosoma cruzi in the acute phase and in the early chronic phase (i.e. children under 16 years old) must be treated, and adults could be treated. In this area, research priorities should target obtaining new drugs to allow shorter treatments with fewer adverse reactions and improving new tools to confirm cure when patients are treated during the Chronic Phase.
本综述旨在描述主要是过去15年中改变针对克氏锥虫感染的特异性治疗标准的知识。
在过去15年中，用于评估抗寄生虫治疗疗效的新方法的使用有所增加。这些工具表明，锥虫杀灭治疗效果的评估期可以缩短。基于恰加斯心肌病可能确实由持续的寄生虫感染引发的假设，锥虫杀灭疗法可能延迟、减轻或预防疾病进展似乎是合理的。
基于目前的知识，我们可以假设，每一位处于急性期和慢性早期（即16岁以下儿童）的克氏锥虫感染患者都必须接受治疗，成人也可以接受治疗。在这一领域，研究重点应是获取新药物以实现疗程更短、不良反应更少的治疗，并改进新工具以在慢性期治疗患者时确认治愈情况。
